Today: 30 April 2026
Meta’s Q3 Showdown: Can AI Spend and Ad Growth Drive Another Rally?
5 November 2025
3 mins read

Meta Stock Today (Nov. 5, 2025): META edges higher after four‑day rout as AI capex, “PG‑13” Instagram dispute and fresh regulation dominate headlines

At a glance (as of 19:55 UTC): Meta Platforms (NASDAQ: META) is trading around the mid‑$630s and modestly higher intraday after a sharp post‑earnings slide last week. The bounce comes amid new scrutiny of Instagram’s teen‑safety labels, ongoing debate over Meta’s record AI spending, and lingering regulatory actions in Europe and India.


Key takeaways

  • Shares stabilize today after a four‑day skid that erased more than $300B in market value following Meta’s plan to lift 2025 capex to $70–$72B and spend even more in 2026 for AI data centers.
  • Instagram “PG‑13” backlash: The Motion Picture Association sent Meta a cease‑and‑desist, calling the “PG‑13” label on teen filters misleading and seeking an immediate stop. Meta says it never claimed official certification and hopes to work with the MPA. Reuters
  • EU & France pressure: France’s equalities watchdog ruled Facebook job‑ad delivery was sexist; Meta disputes the finding. Coverage and commentary kept the issue in the news cycle today.
  • India ruling: An Indian appeals tribunal lifted a WhatsApp data‑sharing ban but upheld a fine, a mixed outcome in Meta’s largest market by users.
  • Balance‑sheet moves: After earnings, Meta lined up a multi‑part bond sale widely reported at $25–$30B to help finance AI infrastructure.

What moved META today

After last week’s sell‑off, broader U.S. markets steadied this morning, helping large‑cap tech rebound and giving META a lift. The stock’s intraday gains, however, came as investors weighed fresh risk headlines around teen safety labels and ad‑delivery algorithms.


The latest Meta headlines on Nov. 5, 2025

  • MPA vs. Instagram’s “PG‑13” — The Motion Picture Association sent a cease‑and‑desist demanding Meta stop using “PG‑13” to describe teen content filters, arguing the comparison is “misleading” and trades on a registered certification mark. Meta says it never implied an official rating and wants to engage with MPA. Reuters
  • “Metaverse déjà vu?” — A morning column noted META fell nearly 17% in four sessions after the AI capex update, drawing parallels with 2022’s metaverse‑spending rout; some analysts even downgraded the stock on capex concerns. Los Angeles Times
  • France’s equality watchdog — The Défenseur des droits said Facebook’s job‑ad distribution created indirect sex discrimination; Meta rejects the ruling. Coverage today kept the story front‑and‑center.

Earnings & spending context (still setting the tone)

In Q3 2025, Meta posted $51.2B in revenue (+26% YoY) and raised full‑year capex guidance to $70–$72B. Reported profit was hit by a ~$16B one‑time U.S. tax charge tied to the administration’s recent tax law; excluding it, net income would have risen sharply. Management also flagged “notably larger” capex in 2026 and guided Q4 revenue to $56–$59B. These numbers underpinned both last week’s sell‑off and today’s cautious rebound. Reuters


Funding the AI build‑out

To finance data‑center scale‑up and AI compute, Meta is tapping the bond market. Reports indicate a $25–$30B multi‑tranche issuance (5‑ to 40‑year maturities), following management’s message that AI spending will step up again next year. Today’s recovery arrives with that financing backdrop still top of mind for credit and equity investors alike.


Regulatory & policy watch

  • Teen safety labels: The MPA’s letter escalates pressure on Instagram’s default teen settings rolled out in October (which Meta had described as being “guided by” PG‑13 standards). Expect ongoing legal/PR wrangling over how platforms describe age‑appropriateness. Reuters
  • Algorithmic bias in ads: France’s ruling adds to years of scrutiny over ad delivery fairness on Facebook; Meta disputes the finding and process. Investors are watching for any mandated product changes that could affect ad targeting.
  • India (WhatsApp): The NCLAT removed the ban on user‑data sharing across Meta apps but kept a monetary penalty — a nuanced outcome but one that reduces operational friction in a key growth market.

Why it matters for the stock

  • Spending vs. payoff: The crux is whether AI investment can expand ad yield, unlock messaging monetization (WhatsApp/Threads), and improve time‑spent enough to justify capex — without the enterprise cloud leverage peers enjoy. That debate is driving day‑to‑day price action.
  • Balance‑sheet capacity: A large bond sale paired with still‑strong operating cash flow gives Meta room to build. But higher fixed charges and capex will keep free cash flow sensitivity in focus each quarter.
  • Regulatory friction: Policy flashpoints (teen safety, ad fairness, privacy) can force product tweaks and add compliance cost — modest near‑term earnings risk, but important to watch because they touch Meta’s targeting and brand safety narratives.

What to watch next

  • Capex cadence in 2026 vs. revenue/FCF trajectory.
  • Debt pricing and demand for the pending bond tranches.
  • Any remediation commitments Meta makes in response to the MPA letter and the French watchdog decision.

Methodology & timestamp: Market data shown in the chart and snapshot reflect LSEG/market prices as of Wed, Nov. 5, 2025, 19:55 UTC. News items were verified from primary outlets on Nov. 5, 2025, with context from coverage over the past week for completeness.

This article is for information only and is not investment advice.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?
Previous Story

Trex Stock Plunges on Earnings Miss – What’s Next for the Decking Leader?

XRP Price Jumps Back After Wild Swing – Ripple’s Token Eyes ETF Catalyst in Volatile Crypto Market
Next Story

XRP Price on Nov. 5, 2025: Ripple’s $500M Funding at a $40B Valuation Meets a Choppy Crypto Market

Go toTop